Another trial, in the phase Ib/II setting, evaluated eprenetapopt with AZA in TP53-mutated myeloid disorders, including MDS and AML, and reported ORR 64% and CR 36% in AML patients [114]. Here, TP53 is linked to acute myeloid leukemia.